

09 Jun 2021 | News

## QUOTED. 9 June 2021. CVRx.

by

CVRx, which markets the implantable baroreflex activation stimulation technology Barostim Neo, plans to raise \$75m in an IPO. See what the company said about it here.

“Our mission is to capitalize upon our first-mover advantage to become the global leader in providing clinically proven, innovative, and minimally invasive neuromodulation solutions that improve the health of patients with HFrEF and other cardiovascular diseases.” – CVRx

- Find out more: [CVRx Raises \\$75M In IPO To Commercialize And Develop Heart Failure Therapy](#)

[Click here](#) for a free trial of *Medtech Insight*